SADDLE BROOK, NJ and AACHEN, GERMANY (February 11, 2013) - CircuLite®, Inc. will be participating at the 42nd Annual meeting of the German Society for Thoracic and Cardiovascular Surgery, being held February 17-20, 2013, in Freiburg, Germany. CircuLite recently announced CE Marking approval for the SYNERGY® System, which is a micro-pump designed to halt the progression of heart failure and to improve symptoms and exercise tolerance. By working with the heart's native pumping capacity, the SYNERGY System is specifically targeted for treatment of ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA III and early IV) who remain symptomatic despite standard medical management.
Company representatives will be available at the CircuLite stand A69 to provide demonstrations, review the latest updates from the CE Mark trial and answer questions about the SYNERGY technology.
About the SYNERGY® Circulatory Support System
The SYNERGY Circulatory Support System is a micro-blood pump that provides up to 4.25 liters of blood per minute and reduces the heart's workload, while improving blood flow to vital organs. The system is surgically implanted using a mini-thoracotomy and is placed in a pacemaker-like pocket. In a clinical study, SYNERGY improved hemodynamics, exercise capacity, and overall quality of life. SYNERGY is designed and manufactured in Aachen, Germany.
CircuLite is developing disruptive solutions to improve the treatment of heart failure. The Company's technologies work in conjunction with the heart to enhance clinical outcomes and improve quality of life. SYNERGY®, which recently received CE Marking approval, features the smallest surgically implanted blood pump for long-term use in patients with heart failure not responding to standard medical treatment. For more information, visit our website at www.circulite.net.